Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spleen aminopeptide oral solution plus entecavir in HBeAg-positive chronic hepatitis B
ChiCTR2300073098Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of spleen polypeptide and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Effect on T cell subsets in peripheral blood of patients receiving experimental group. Started Mar 2023; status: recruiting.
02
Drugs
spleen polypeptideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2300073098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073098.